New understanding and approaches to treatment in rheumatoid arthritis

British Medical Bulletin

Volumn 94, Issue 1, 2010, Pages 201-214

  Tayar, Jean H ^a   Suarez Almazor, Maria E ^a  

^a Department of General Internal Medicine   (United States)

Author keywords

Biologic agents; Disease modifying drugs; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLD; GOLIMUMAB; HLA DR ANTIGEN; HYDROXYCHLOROQUINE; INFLIXIMAB; JANUS KINASE INHIBITOR; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OCRELIZUMAB; OFATUMUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; ANTIRHEUMATIC AGENT;

ADULT; AGAMMAGLOBULINEMIA; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; GENETIC RISK; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INJECTION SITE REACTION; JOINT DESTRUCTION; LOW DRUG DOSE; MEDLINE; MONOTHERAPY; OCCUPATIONAL THERAPY; PALLIATIVE THERAPY; PATHOGENESIS; PHYSIOTHERAPY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SMOKING; ARTHRITIS, RHEUMATOID;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE;

EID: 77952978913     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldq007     Document Type: Review

References (62)

1. Firestein G. Etiology and pathogenesis of rheumatoid arthritis. In: Harris ED Jr, Ruddy S et al. (eds) Kelley's Textbook of Rheumatology, 7th edn. Philadelphia, PA: WB Saunders, 2005,996-1042.
2. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118:3537-3545
3. Connell L, McInnes IB. New cytokine targets in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol 2006;20:865-878
4. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
5. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-911
6. Matsui T, Shimada K, Ozawa N et al. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis. J Rheumatol 2006;33:2390-2397
7. Nishimura K, Sugiyama D, Kogata Y et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808.
8. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann N Y Acad Sci 2008;1143:268-285
9. Liao KP, Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis. Curr Opin Rheumatol 2009;21:279-283
10. Karlson EW, Lee IM, Cook NR et al. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum 1999;42:910-917
11. Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 2000;27:630-637
12. Hughes LB, Morrison D, Kelley JM et al. The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. Arthritis Rheum 2008;58:349-358
13. Daha NA, Kurreeman FA, Marques RB et al. Confirmation of STAT4, IL2/IL21, and CTLA4 polymorphisms in rheumatoid arthritis. Arthritis Rheum 2009;60:1255-1260
14. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006;355:704-712
15. Avina-Zubieta JA, Choi HK, Sadatsafavi M et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-1697
16. Emery P, Breedveld FC, Dougados M et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002;61:290-297
17. American College of Rheumatology Subcommity on Rheumatoid Arthritis. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-346
18. Mitchell KL, Pisetsky DS. Early rheumatoid arthritis. Curr Opin Rheumatol 2007;19:278-283
19. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-1308
20. Tengstrand B, Larsson E, Klareskog L et al. Randomized withdrawal of long-term predniso-lone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density. Scand J Rheumatol 2007;36:351-358
21. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995;333:142-146
22. Svensson B, Boonen A, Albertsson K et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005;52:3360-3370
23. Kirwan John R, Bijlsma Johannes WJ, Boers M et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 2007.
24. Suarez-Almazor Maria E, Belseck E, Shea B et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 1998.
25. Suarez-Almazor Maria E, Belseck E, Shea B et al. Sulfasalazine for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 1998.
26. Suarez-Almazor Maria E, Belseck E, Shea B et al. Antimalarials for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 2000.
27. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-784
28. Osiri M, Shea B, Welch V et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 2002.
29. Saunders SA, Capell HA, Stirling A et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 2008;58:1310-1317
30. Donahue KE, Gartlehner G, Jonas DE et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124-134
31. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 2008;58:S126-S135.
32. Villeneuve E, Emery P. Rheumatoid arthritis: what has changed? Skeletal Radiol 2009;38:109-112
33. Combe B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Clin Rheumatol 2007;21:27-42.
34. Suarez-Almazor Maria E, Belseck E, Shea B et al. Cyclophosphamide for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 2000.
35. Suarez-Almazor Maria E, Spooner C, Belseck E. Azathioprine for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 2000.
36. Wells George A, Haguenauer D, Shea B et al. Cyclosporine for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 1998.
37. van der Kooij SM, Allaart CF, Dijkmans BA et al. Innovative treatment strategies for patients with rheumatoid arthritis. Curr Opin Rheumatol 2008;20:287-294
38. Castro-Rueda H, Kavanaugh A. Biologic therapy for early rheumatoid arthritis: the latest evidence. Curr Opin Rheumatol 2008;20:314-319
39. Mertens M, Singh Jasvinder A. Anakinra for rheumatoid arthritis. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 2009.
40. Gartlehner G, Hansen RA, Jonas BL et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006;33:2398-2408
41. National Institute for Health and Clinical Excellence. The management of rheumatoid arthritis in adults (Clinical guideline 79). London: NICE 2009. www.nice.org.uk/CG79 (last accessed January 28 2010).
42. van der Heijde DM. Overview of radiologic efficacy of new treatments. Rheum Dis Clin North Am 2004;30:285-93, vi.
43. Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-382
44. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003;30:167-178
45. Marshall NJ, Wilson G, Lapworth K et al. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study. Rheumatology (Oxford) 2004;43:1034-1038
46. Fernandez-Nebro A, Irigoyen MV, Urena I et al. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. J Rheumatol 2007;34:2334-2342
47. Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 2005;34:34-38
48. Tubach F, Salmon D, Ravaud P et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-1894
49. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-2895
50. Kremer JM, Genant HK, Moreland LW et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008;58:953-963
51. Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008;58:1566-1575
52. Higashida J, Wun T, Schmidt S et al. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol 2005;32:2109-2115
53. Keystone E, Burmester GR, Furie R et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2008;59:785-793
54. McGonagle D, Tan AL, Madden J et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford) 2008;47:865-867
55. Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69:88-96.
56. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-1523
57. Schiff M, Keiserman M, Codding C et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-1103
58. Cohen SB, Dore RK, Lane NE et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicen-ter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58:1299-1309
59. Deighton C, O'Mahony R, Tosh J et al. Management of rheumatoid arthritis: summary of NICE guidance. BMJ 2009;338:b702.
60. Luqmani R, Hennell S, Estrach C et al. British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford) 2006;45:1167-1169
61. Luqmani R, Hennell S, Estrach C et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford) 2009;48:436-439
62. Combe B, Landewe R, Lukas C et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.